Atopic Dermatitis / Eczema
Conditions
Interventions
XZ.700 or placebo
Sponsors
Micreos Human Health
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Male and female subjects with mild to moderate AD (IGA 2 or 3) 18 to 65 years (during covid-19 restriction period subjects will be included from 18 to 54 years of age inclusive) of age, inclusive. The health status is verified by absence of evidence of any clinically significant active or uncontrolled chronic disease other than AD that potentially may influence the adherence to the study and/or assessments in the study, following a detailed medical history and a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, virology and urinalysis; 2. Diagnosed with AD according to the Hanifin criteria (Hanifin 1980); 3. Suitable target lesion (preferably the antecubital fossa) defined as an eczema lesion of 0,5%*BSA*5% (excluding the face and hands) with at least mild erythema and mild induration at screening and baseline day 1; 4. Target lesion is cultured positive for S. aureus on two consecutive occasions during the screening period; 5. Extent of lesional, atopic dermatits affected skin for 1%*BSA*15%; at screening and baseline (day 1); 6. Willing to refrain from washing the target lesion 12 hours before every study visit that includes microbiology samples; 7. Willing to use microbiome friendly wash solution as provided by sponsor and refrain from other products for washing from screening until end-of-study; 8. Willing to refrain from all topical products for lesional skin during the treatment period; 9. Subjects and their Partners of childbearing potential must use effective contraception, for the duration of the study and for 3 months after the last dose; 10. Able to Participate and willing to give written informed consent and to comply with the study restrictions; 11. Has the ability to communicate well with the Investigator in the Dutch language.
Exclusion criteria
Exclusion criteria: 1. Any current and / or recurrent clinically significant skin condition which will interfere with the clinical findings of the study as assessed by the investigator; 2. Ongoing use of prohibited atopic dermatitis treatments. Washout periods prior to baseline (first dose of the study drug) are as follows: - All atopic dermatitis lesions: any topical medication (prescription or over-the-counter [OTC]): 14 days. For emollients target lesion only: 7 days. On other atopic dermatitis lesions use of emollients is allowed, however must be discontinued prior to Day 1. - Cyclosporine/oral steroids/azathioprine/mycophenolate mofetil/other systemic AD drugs: 4 weeks - Phototherapy: 3 weeks - Biologics: 5 half-lives of the drug - Systemic antibiotics: 14 days 3. Tanning due to sunbathing, excessive sun exposure or a tanning booth within 3 weeks of enrolment and/or not willing to refrain from these during the study; 4. Known hypersensitivity to the investigational compound or its excipients; 5. Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding; 6. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year; 7. Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening; 8. A positive drug and/or alcohol test at screening (rescreening is allowed). 9. Subject has a body temperature of >38.0 °C at any visit, only during SARS-CoV-2 measures; 10. Only during SARS-CoV-2 measures: Subject has a BMI of >30 kg/m2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tolerability / safety endpoints - Adverse events (AE) - Laboratory safety testing (blood and urine) - 12-Lead ECGs - Vital signs - Physical examination - Skin irritation by local irritation grading scale (Part A only) Adherence * Electronic diary with photo capture function to monitor treatment compliance | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacodynamic endpoints Pharmacodynamic effects of XZ.700 will be assessed at the time points indicated in the Visit and Assessment Schedule (Table 1 & 2) by: - Multispectral imaging (erythema and roughness of target lesion) - Laser speckle contrast imaging (LSCI, blood flow of target lesion) - 2D photo documentation of the target lesion - Microbiome of skin lesions (of target lesion and non-lesional skin) - Bacterial colonization of skin lesions (S. aureus cultures of target lesion and non-lesional skin) - Local (biopsy) biomarkers may comprise, but are not limited to: IL-13, IL-4, IL-5, IL-33, TSLP, IL-31, IL-22, eotaxin - Transepidermal water loss of lesional and non-lesional skin - Blood-based biomarkers Efficacy endpoints Efficacy of XZ.700 will be assessed at the time points indicated in the Visit and Assessment Schedule (Table 1 & 2): * SCORAD; EASI, IGA, lesion count, lesion clearance * Target lesion oSCORAD, TSS and surface area (BSA in cm2) * Patient-reported itch (twice daily NRS by e-diary / mobile app and POEM) * DLQI | — |
Countries
Netherlands
Outcome results
None listed